PATENT CLAIM ANALYSIS

Application Number: 15945231
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "250000"]

Abstract:
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

Claim (Index 120):
The extended release solid dosage form of  claim 119 , wherein the organic acid is tartaric acid.

Metadata:
- Claim Count in Document: 119.0
- Percentile: 91.0
- Lexical Diversity: 1.43902
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15945225', '15857892', '15908347', '15682457', '15803538']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.906913506635458
- 35 USC 102 Novelty (BERT): 0.6729989353043517
- Combined Prediction Score: 0.8835220495023475
- Mean Citation Score: 766.0807000000003
- Max Citation Score: 794.1041
- Similarity Product: 647.7485327678262

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test